| 1 | English French Notes Complete/Exclude
|
|---|
| 2 | 528 FINE NEEDLE ASPIRATION......
|
|---|
| 3 | 529 CORE NEEDLE BIOPSY..........
|
|---|
| 4 | 530 INCISIONAL BIOPSY...........
|
|---|
| 5 | 531 EXCISIONAL BIOPSY...........
|
|---|
| 6 | 518OUTSIDE CONFIRMATION OF BIOPSY
|
|---|
| 7 | PRIMARY SITE..................:
|
|---|
| 8 | HISTOLOGY/BEHAVIOR CODE.......:
|
|---|
| 9 | 520ADDNL GRADE CODING SYSTEM.....
|
|---|
| 10 | 521VALUE OF ADDNL CODING SYSTEM..
|
|---|
| 11 | 26DIAGNOSTIC CONFIRMATION.......
|
|---|
| 12 | PRETREATMENT TUMOR SIZE (mm)
|
|---|
| 13 | PATHOLOGIC TUMOR SIZE (mm)
|
|---|
| 14 | DEPTH OF TUMOR
|
|---|
| 15 | 29PRETREATMENT TUMOR SIZE (mm)...
|
|---|
| 16 | 522PATHOLOGIC TUMOR SIZE (mm).....
|
|---|
| 17 | 523DEPTH OF TUMOR.................
|
|---|
| 18 | CONSULTATIONS:
|
|---|
| 19 | 524 MEDICAL ONCOLOGIST...........
|
|---|
| 20 | 525 RADIATION ONCOLOGIST.........
|
|---|
| 21 | TREATING SURGEON................: Not applicable, no surgery
|
|---|
| 22 | ASA CLASS.......................: Class unknown or not applicable
|
|---|
| 23 | POSTOPERATIVE DEATH.............: Not applicable, no surgery
|
|---|
| 24 | 526 TREATING SURGEON................
|
|---|
| 25 | 527 ASA CLASS.......................
|
|---|
| 26 | 441 POSTOPERATIVE DEATH.............
|
|---|
| 27 | EXTERNAL BEAM RADIATION.........: No
|
|---|
| 28 | INTRAOPERATIVE RADIATION........: No
|
|---|
| 29 | EXTERNAL BEAM RADIATION.........: Unknown
|
|---|
| 30 | INTRAOPERATIVE RADIATION........: Unknown
|
|---|
| 31 | 532 EXTERNAL BEAM RADIATION.........
|
|---|
| 32 | 533 NUMBER OF FRACTIONS...........
|
|---|
| 33 | 534 RADIATION ENERGY (MV).........
|
|---|
| 34 | 567 DATE THERAPY STARTED..........
|
|---|
| 35 | 361 DATE THERAPY ENDED............
|
|---|
| 36 | 535 INTRAOPERATIVE RADIATION........
|
|---|
| 37 | 537 RADIATION ENERGY (MV).........
|
|---|
| 38 | 539 NUMBER OF DAYS GIVEN..........
|
|---|
| 39 | 541 DATE THERAPY STARTED..........
|
|---|
| 40 | 542 DATE THERAPY ENDED............
|
|---|
| 41 | 51.3 RADIATION/SURGERY SEQUENCE......
|
|---|
| 42 | NUMBER OF FRACTIONS...........: 000
|
|---|
| 43 | RADIATION ENERGY (MV).........: 00
|
|---|
| 44 | DATE THERAPY STARTED..........: 00/00/0000
|
|---|
| 45 | DATE THERAPY ENDED............: 00/00/0000
|
|---|
| 46 | NUMBER OF FRACTIONS...........: 999
|
|---|
| 47 | RADIATION ENERGY (MV).........: 99
|
|---|
| 48 | DATE THERAPY STARTED..........: 99/99/9999
|
|---|
| 49 | DATE THERAPY ENDED............: 99/99/9999
|
|---|
| 50 | NUMBER OF DAYS GIVEN..........: 000
|
|---|
| 51 | NUMBER OF DAYS GIVEN..........: 999
|
|---|
| 52 | DATE OF CHEMOTHERAPY............:
|
|---|
| 53 | AGENTS ADMINISTERED, METHODS OF DELIVERY AND LOCATIONS:
|
|---|
| 54 | CISPLATIN.........: No DOXORUBICIN.......: No
|
|---|
| 55 | METHOD OF DELIVERY: Not applicable METHOD OF DELIVERY: Not applicable
|
|---|
| 56 | LOCATION..........: Not applicable LOCATION..........: Not applicable
|
|---|
| 57 | CYTOXAN...........: No ETOPOSIDE.........: No
|
|---|
| 58 | DTIC..............: No IFOSFAMIDE........: No
|
|---|
| 59 | METHOD OF DELIVERY..............: Not applicable
|
|---|
| 60 | LOCATION........................: Not applicable
|
|---|
| 61 | METHOD OF DELIVERY..............: Unknown
|
|---|
| 62 | 547 METHOD OF DELIVERY..............
|
|---|
| 63 | 548 METHOD OF DELIVERY..............
|
|---|
| 64 | 549 METHOD OF DELIVERY..............
|
|---|
| 65 | 550 METHOD OF DELIVERY..............
|
|---|
| 66 | 551 METHOD OF DELIVERY..............
|
|---|
| 67 | 552 METHOD OF DELIVERY..............
|
|---|
| 68 | 559 COLONY STIMULATING FACTORS......
|
|---|
| 69 | 560 NATIONAL TREATMENT PROTOCOL.....
|
|---|
| 70 | 561 OTHER PROTOCOL..................
|
|---|
| 71 | 562 REFERRED TO REHAB SERVICES......
|
|---|
| 72 | 563 CONSULT W PHYSICAL THERAPY/REHAB
|
|---|
| 73 | 564 TRANSFERRED TO REHAB FACILITY...
|
|---|
| 74 | 565 NO OF HOSPITALIZATIONS W/I 6 MO.
|
|---|
| 75 | 566 TOTAL LENGTH OF STAYS...........
|
|---|
| 76 | DISTANT SITE(S) OF RECURRENCE
|
|---|
| 77 | SUBSEQUENT TREATMENT FOR RECURRENCE OR PROGRESSION
|
|---|
| 78 | TABLE V - FIRST RECURRENCE AND SUBSEQUENT TREATMENT
|
|---|
| 79 | NO SUBSEQUENT TREATMENT
|
|---|
| 80 | .07 HORMONE THERAPY
|
|---|
| 81 | ACCESSION NUMBER..................:
|
|---|
| 82 | SEQUENCE NUMBER...................:
|
|---|
| 83 | POSTAL CODE AT DIAGNOSIS..........:
|
|---|
| 84 | DATE OF BIRTH.....................:
|
|---|
| 85 | RACE..............................:
|
|---|
| 86 | SPANISH ORIGIN....................:
|
|---|
| 87 | SEX...............................:
|
|---|
| 88 | PRIMARY PAYER AT DIAGNOSIS........:
|
|---|
| 89 | FAMILY HIST OF SOFT TISSUE SARCOMA:
|
|---|
| 90 | PERSONAL HISTORY OF ANY CANCER....:
|
|---|
| 91 | CLASS OF CASE.....................:
|
|---|
| 92 | ANGIOGRAM OF PRIMARY............:
|
|---|
| 93 | BONE MARROW ASPIRATE/BIOPSY.....:
|
|---|
| 94 | BONE SCAN.......................:
|
|---|
| 95 | CT SCAN OF CHEST................:
|
|---|
| 96 | CT SCAN OF PRIMARY..............:
|
|---|
| 97 | LIVER FUNCTION STUDIES..........:
|
|---|
| 98 | MRI OF PRIMARY..................:
|
|---|
| 99 | MRI OF OTHER....................:
|
|---|
| 100 | ELECTRON MICROSCOPY.............:
|
|---|
| 101 | FLOW CYTOMETRY..................:
|
|---|
| 102 | IN SITU HYBRIDIZATION...........:
|
|---|
| 103 | BIOPSIES: HISTOLOGY/BEHAVIOR/GRADE
|
|---|
| 104 | FINE NEEDLE ASPIRATION..........:
|
|---|
| 105 | CORE NEEDLE ASPIRATION..........:
|
|---|
| 106 | INCISIONAL BIOPSY...............:
|
|---|
| 107 | EXCISIONAL BIOPSY...............:
|
|---|
| 108 | OUTSIDE CONFIRMATION OF BIOPSY....:
|
|---|
| 109 | DATE OF INITIAL DIAGNOSIS.........:
|
|---|
| 110 | PRIMARY SITE......................:
|
|---|
| 111 | SUBSITE...........................:
|
|---|
| 112 | HISTOLOGY/BEHAVIOR CODE...........:
|
|---|
| 113 | GRADE.............................:
|
|---|
| 114 | ADDNL GRADE CODING SYSTEM.........:
|
|---|
| 115 | VALUE OF ADDNL CODING SYSTEM......:
|
|---|
| 116 | DIAGNOSTIC CONFIRMATION...........:
|
|---|
| 117 | PRETREATMENT TUMOR SIZE (mm)......:
|
|---|
| 118 | PATHOLOGIC TUMOR SIZE (mm)........:
|
|---|
| 119 | DEPTH OF TUMOR....................:
|
|---|
| 120 | MULTIFOCAL........................:
|
|---|
| 121 | REGIONAL NODES EXAMINED...........:
|
|---|
| 122 | REGIONAL NODES POSITIVE...........:
|
|---|
| 123 | SITE OF DISTANT METASTASIS #1...:
|
|---|
| 124 | SITE OF DISTANT METASTASIS #2...:
|
|---|
| 125 | SITE OF DISTANT METASTASIS #3...:
|
|---|
| 126 | AJCC STAGE......................:
|
|---|
| 127 | CLINICAL STAGED BY..............:
|
|---|
| 128 | PATHOLOGIC STAGED BY............:
|
|---|
| 129 | MEDICAL ONCOLOGIST..............:
|
|---|
| 130 | RADIATION ONCOLOGIST............:
|
|---|
| 131 | Print Soft Tissue Sarcoma PCE
|
|---|
| 132 | PCE Study of Soft Tissue Sarcoma
|
|---|
| 133 | FIRST COURSE TREATMENT DATE.......:
|
|---|
| 134 | RESIDUAL PRIMARY TUMOR..........:
|
|---|
| 135 | TREATING SURGEON................:
|
|---|
| 136 | ASA CLASS.......................:
|
|---|
| 137 | POSTOPERATIVE DEATH.............:
|
|---|
| 138 | EXTERNAL BEAM RADIATION...:
|
|---|
| 139 | BRACHYTHERAPY...........:
|
|---|
| 140 | NUMBER OF FRACTIONS.......:
|
|---|
| 141 | NUMBER OF DAYS GIVEN....:
|
|---|
| 142 | DOSE....................:
|
|---|
| 143 | RADIATION ENERGY (MV).....:
|
|---|
| 144 | DATE THERAPY STARTED....:
|
|---|
| 145 | DATE THERAPY STARTED......:
|
|---|
| 146 | DATE THERAPY ENDED......:
|
|---|
| 147 | DATE THERAPY ENDED........:
|
|---|
| 148 | INTRAOPERATIVE RADIATION..:
|
|---|
| 149 | RADIATION/SURGERY SEQUENCE:
|
|---|
| 150 | DATE OF CHEMOTHERAPY:
|
|---|
| 151 | AGENT ADMINISTERED METHOD OF DELIVERY LOCATION
|
|---|
| 152 | COLONY STIMULATION FACTOR........:
|
|---|
| 153 | NATIONAL TREATMENT PROTOCOL......:
|
|---|
| 154 | OTHER PROTOCOL...................:
|
|---|
| 155 | REFERRED TO REHAB SERVICES.......:
|
|---|
| 156 | CONSULT W PHYSICAL THERAPY/REHAB.:
|
|---|
| 157 | TRANSFERRED TO REHAB FACILITY....:
|
|---|
| 158 | NO OF HOSPITALIZATIONS W/I 6 MO..:
|
|---|
| 159 | TOTAL LENGTH OF STAYS............:
|
|---|
| 160 | TYPE OF FIRST RECURRENCE..........:
|
|---|
| 161 | OTHER TYPE OF FIRST RECURRENCE....:
|
|---|
| 162 | DISTANT SITE(S) OF FIRST RECURRENCE:
|
|---|
| 163 | RECURRENCE SITE 1.................:
|
|---|
| 164 | RECURRENCE SITE 2.................:
|
|---|
| 165 | RECURRENCE SITE 3.................:
|
|---|
| 166 | NO SUBSEQUENT TREATMENT
|
|---|
| 167 | HORMONE THERAPY:
|
|---|
| 168 | SURGERY OF PRIMARY SITE DATE...:
|
|---|
| 169 | SCOPE OF LYMPH NODE SURGERY...:
|
|---|
| 170 | RECON/RESTORE - DELAYED.......:
|
|---|
| 171 | RECON/RESTORE - DELAYED DATE..:
|
|---|
| 172 | too long:
|
|---|
| 173 | Text should not exceed NAACCR length of
|
|---|
| 174 | Do you want to re-edit this field
|
|---|
| 175 | Patient Care Evaluation Study of Thyroid Cancer
|
|---|
| 176 | FAMILY HISTORY OF THYROID CANCER
|
|---|
| 177 | PERSONAL HISTORY OF NON-THYROID CANCER
|
|---|
| 178 | PRIOR EXPOSURE TO RADIATION
|
|---|
| 179 | PERSONAL HISTORY OF GOITER
|
|---|
| 180 | FAMILY HISTORY OF THYROID DISEASE
|
|---|
| 181 | PERSONAL HISTORY OF GRAVES DISEASE
|
|---|
| 182 | PERSONAL HISTORY OF THYROIDITIS
|
|---|
| 183 | FAMILY HISTORY OF GOITER OR OTHER THYROID DISEASE
|
|---|
| 184 | 9POSTAL CODE AT DIAGNOSIS..........
|
|---|
| 185 | 9SPANISH ORIGIN....................
|
|---|
| 186 | 18PRIMARY PAYER AT DIAGNOSIS........
|
|---|
| 187 | 400FAMILY HISTORY OF THYROID CANCER..
|
|---|
| 188 | PERSONAL HISTORY OF NON-THYROID CANCER:
|
|---|
| 189 | 402 CHILDHOOD MALIGNANCY............
|
|---|
| 190 | 403PRIOR EXPOSURE TO RADIATION.......
|
|---|
| 191 | 404PERSONAL HISTORY OF GOITER........
|
|---|
| 192 | 405FAMILY HISTORY THYROID DISEASE....
|
|---|
| 193 | 406PERSONAL HISTORY OF GRAVES DISEASE
|
|---|
| 194 | 407PERSONAL HISTORY OF THYROIDITIS...
|
|---|
| 195 | SYMPTOMS/SIGNS PRESENT
|
|---|
| 196 | DIAGNOSTIC/SURGICAL WORKUP
|
|---|
| 197 | HISTOLOGY/BEHAVIOR CODE (ICD-O-2)
|
|---|
| 198 | BLOOD VESSEL INVASION
|
|---|
| 199 | EXTRA-THYROID EXTENSION
|
|---|
| 200 | SYMPTOMS/SIGNS PRESENT:
|
|---|
| 201 | 409 HOARSENESS OR VOICE CHANGE.....
|
|---|
| 202 | 410 NECK NODAL MASS................
|
|---|
| 203 | 413 PATHOLOGIC FRACTURE............
|
|---|
| 204 | 414 STRIDOR OR DIFFICULTY BREATHING
|
|---|
| 205 | 415 THYROID MASS...................
|
|---|
| 206 | 416 WEIGHT LOSS....................
|
|---|
| 207 | DIAGNOSTIC/SURGICAL WORKUP:
|
|---|
| 208 | 418 BONE SCAN......................
|
|---|
| 209 | 420 CT SCAN OF NECK................
|
|---|
| 210 | 422 INCISIONAL BIOPSY..............
|
|---|
| 211 | 425 NEEDLE ASPIRATION OF NECK NODE.
|
|---|
| 212 | 426 NEEDLE ASPIRATION OF THYROID...
|
|---|
| 213 | 427 MRI OF NECK....................
|
|---|
| 214 | 428 THYROID SCAN...................
|
|---|
| 215 | 429 ULTRASOUND OF THYROID..........
|
|---|
| 216 | HISTOLOGY/BEHAVIOR CODE (ICD-O-2):
|
|---|
| 217 | 431BLOOD VESSEL INVASION............
|
|---|
| 218 | 432EXTRA-THYROIDAL EXTENSION........
|
|---|
| 219 | SIZE OF TUMOR
|
|---|
| 220 | LOCATION OF POSITIVE NODES
|
|---|
| 221 | 29SIZE OF TUMOR..................
|
|---|
| 222 | 434LOCATION OF POSITIVE NODES.....
|
|---|
| 223 | 19CLINICAL STAGE..................
|
|---|
| 224 | 89PATHOLOGIC STAGE................
|
|---|
| 225 | DATE OF FIRST COURSE TREATMENT.......:
|
|---|
| 226 | DATE OF NON CANCER-DIRECTED SURGERY:
|
|---|
| 227 | NON CANCER-DIRECTED SURGERY........:
|
|---|
| 228 | DATE OF SURGERY OF PRIMARY SITE....:
|
|---|
| 229 | DATE OF DISCHARGE AFTER SURGERY....: 00/00/0000
|
|---|
| 230 | 435 DATE OF DISCHARGE AFTER SURGERY....
|
|---|
| 231 | SURGERY OF PRIMARY SITE............:
|
|---|
| 232 | RESIDUAL PRIMARY TUMOR.............: NA
|
|---|
| 233 | AIRWAY PROBLEM REQ TRACHEOSTOMY..: Not applicable, no surgery
|
|---|
| 234 | BLEEDING HEMATOMA................: Not applicable, no surgery
|
|---|
| 235 | HYPOCALCEMIA.....................: Not applicable, no surgery
|
|---|
| 236 | RECURRENT NERVE INJURY...........: Not applicable, no surgery
|
|---|
| 237 | WOUND INFECTION..................: Not applicable, no surgery
|
|---|
| 238 | POSTOPERATIVE DEATH WITH 30 DAYS.: Not applicable, no surgery
|
|---|
| 239 | 59 RESIDUAL PRIMARY TUMOR.............
|
|---|
| 240 | 436 AIRWAY PROBLEM REQ TRACHEOSTOMY..
|
|---|
| 241 | 437 BLEEDING HEMATOMA................
|
|---|
| 242 | 439 RECURRENT NERVE INJURY...........
|
|---|
| 243 | 440 WOUND INFECTION..................
|
|---|
| 244 | 441 POSTOPERATIVE DEATH WITHIN 30 DAYS.
|
|---|
| 245 | RADIATION:
|
|---|
| 246 | DATE RADIATION STARTED.............:
|
|---|
| 247 | REGIONAL RAD (cGy) DOSE............: 00000
|
|---|
| 248 | BOOST DOSAGE.......................: 00000
|
|---|
| 249 | TOTAL MILLICURIES (mCi) OF RADIOIODINE:
|
|---|
| 250 | INITAL DOSE........................: 00000
|
|---|
| 251 | SECOND DOSE........................: 00000
|
|---|
| 252 | REGIONAL RAD (cGy) DOSE............: 99999
|
|---|
| 253 | BOOST DOSAGE.......................: 99999
|
|---|
| 254 | INITAL DOSE........................: 99999
|
|---|
| 255 | SECOND DOSE........................: 99999
|
|---|
| 256 | 442 REGIONAL RAD (cGy) DOSE............
|
|---|
| 257 | 443 BOOST DOSAGE.......................
|
|---|
| 258 | 444 INITIAL DOSE.......................
|
|---|
| 259 | 445 SECOND DOSE........................
|
|---|
| 260 | ADJUVANT CHEMO W BEAM RADIATION....: No concomitant treatment
|
|---|
| 261 | ADJUVANT CHEMO W BEAM RADIATION....: Unknown if therapy concomitant
|
|---|
| 262 | 446 ADJUVANT CHEMO W BEAM RADIATION....
|
|---|
| 263 | THYROID HORMONE THERAPY............:
|
|---|
| 264 | FAMILY HISTORY OF THYROID CANCER..:
|
|---|
| 265 | CHILDHOOD MALIGNANCY............:
|
|---|
| 266 | PRIOR EXPOSURE TO RADIATION.......:
|
|---|
| 267 | PERSONAL HISTORY OF GOITER........:
|
|---|
| 268 | FAMILY HISTORY OF THYROID DISEASE.:
|
|---|
| 269 | PERSONAL HISTORY OF GRAVES DISEASE:
|
|---|
| 270 | PERSONAL HISTORY OF THYROIDITIS...:
|
|---|
| 271 | TABLE II - INITIAL DIAGNOSIS/CANCER IDENTIFICATION
|
|---|
| 272 | HOARSENESS OR VOICE CHANGE......:
|
|---|
| 273 | NECK NODAL MASS.................:
|
|---|
| 274 | PATHOLOGIC FRACTURE.............:
|
|---|
| 275 | STRIDOR/DIFFICULTY BREATHING....:
|
|---|
| 276 | THYROID MASS....................:
|
|---|
| 277 | WEIGHT LOSS.....................:
|
|---|
| 278 | DIAGNOISTIC/SURGICAL WORKUP:
|
|---|
| 279 | CT SCAN OF NECK.................:
|
|---|
| 280 | NEEDLE ASPIRATION OF NECK NODE..:
|
|---|
| 281 | NEEDLE ASPIRATION OF THYROID....:
|
|---|
| 282 | MRI OF NECK.....................:
|
|---|
| 283 | THYROID SCAN....................:
|
|---|
| 284 | ULTRASOUND OF THYROID...........:
|
|---|
| 285 | PRIMARY SITE (ICD-O-2)............:
|
|---|
| 286 | HISTOLOGY/BEHAVIOR CODE (ICD-O-2).:
|
|---|
| 287 | BLOOD VESSEL INVASION.............:
|
|---|
| 288 | EXTRA-THYROIDAL EXTENSION.........:
|
|---|
| 289 | SIZE OF TUMOR (mm)................:
|
|---|
| 290 | LOCATION OF POSITIVE NODES........:
|
|---|
| 291 | CLINICAL STAGE................:
|
|---|
| 292 | PATHOLOGIC STAGE..............:
|
|---|
| 293 | Print Thyroid PCE
|
|---|
| 294 | PCE Study of Thyroid Cancer
|
|---|
| 295 | DISCHARGE AFTER SURGERY DATE....:
|
|---|
| 296 | AIRWAY PROBLEM W TRACHEOSTOMY.:
|
|---|
| 297 | BLEEDING HEMOTOMA.............:
|
|---|
| 298 | RECURRENT NERVE INJURY........:
|
|---|
| 299 | WOUND INFECTION...............:
|
|---|
| 300 | POSTOPERATIVE DEATH W/I 30 DAYS.:
|
|---|
| 301 | REGIONAL RAD (cGy) DOSE.........:
|
|---|
| 302 | BOOST DOSAGE....................:
|
|---|
| 303 | #################### #################### ####################
|
|---|
| 304 | #################### #################### ####################
|
|---|
| 305 | #################### #################### ####################
|
|---|
| 306 | #################### #################### ####################
|
|---|
| 307 | #################### #################### ####################
|
|---|
